⚖
Compare Funds
See how two funds stack up side by side, real returns, risk, cost and portfolio overlap.
VS
Key Metrics Comparison
| Metric | HDFC Innovation Fund - Growth - Direct Plan | HDFC Pharma and Healthcare Fund - Growth - Direct Plan |
|---|---|---|
| Snapshot | ||
| AMC | HDFC MF | HDFC MF |
| Category | Equity - Thematic Fund - Other | Equity - Sectoral Fund - Pharma & Health Care |
| NAV | ₹11.52 (30 Oct 2026) | ₹21.95 (30 Oct 2026) |
| Rating | ★★★ | ★★★★★ |
| Benchmark | NIFTY 500 - TRI | BSE Health Care - TRI |
| Fund Manager | Amit Sinha | Nikhil Mathur |
| Inception | 17 Jul 2025 | 04 Oct 2023 |
| Returns | ||
| 1Y | 9.94% | 22.64% |
| 3Y | — | 30.41% |
| 5Y | — | — |
| Since Inception | 11.56% | 29.15% |
| Risk | ||
| 13.90 | 14.07 | |
| 0.93 | 0.59 | |
| 0.68 | 1.59 | |
| 16.16 | 21.67 | |
| 1.49 | 3.48 | |
| -7.73% | -9.23% | |
| Costs | ||
| Expense Ratio | 1.02% | 1.03% |
| Exit Load | 1% on or before 1M, Nil after 1M | 1% on or before 30D, Nil after 30D |
| Min SIP | ₹100 | ₹100 |
| Min Lumpsum | ₹100 | ₹100 |
| Lock-in | None | None |
Min SIP is reported per fund, not per plan, every plan of a fund shares the same figure.
Portfolio Overlap
HDFC MF85%
HDFC MF85%
15.3%Only 15.3% of holdings by weight are common between HDFC MF and HDFC MF, based on each fund's top 20 disclosed holdings, not the full portfolio.
Common holdingHDFC MFHDFC MF
TREPS - Tri-party Repo4.96%4.67%
Divi's Laboratories Ltd.3.32%9.39%
Sun Pharmaceutical Industries Ltd.2.54%8.28%
Rubicon Research Ltd.3.21%2.52%
Torrent Pharmaceuticals Ltd.2.25%3.65%
Category context: Equity vs Equity. Open the full Screener →